The Europe Multiple Myeloma Therapeutics Market was worth USD 1.98 billion in 2019 and estimated to be growing at a CAGR of 4.58%, to reach USD 2.47 billion by 2024.
Europe is the second largest market among regions after North America.
The Multiple Myeloma (MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2019 and 2024. As multiple myeloma is mostly irredeemable and is regularly characterized by a cycle of reduction and relapse, there is an acute need for new treatments for patients that work in distinctive and innovative ways.
Improved investments in R&D in the pharmaceutical area, absence of healing drugs for blood diseases and the introduction of advanced drugs have fuelled the growth of multiple myeloma therapeutics market. Therapies such as radiation therapy, chemotherapy, physiotherapy, and biological therapy have huge potential to outgrowth the market. The patent terminations of some bestselling drugs have obstructed the growth of the market.
This research report segmented and sub-segmented into the following categories:
Regionally, France is the largest market for multiple myeloma therapeutics in the European region while Italy and Spain are estimated to grow at the highest CAGR.
Key players operating in the Europe Multiple Myeloma Therapeutics Market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc. and Johnson and Johnson.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Anthracycline antibiotic
5.1.1.2 Alkylating agent
5.1.2 Targeted Therapy
5.1.2.1 Proteasome inhibitor
5.2 By Drug Type
5.2.1 Corticosteroids
5.2.1.1 Dexamethasone (Decadron)
5.2.1.2 Prednisone (Deltasone/Orasone)
5.2.2 Immunomodulatory agents
5.2.2.1 Thalidomide (Thalomid)
5.2.2.2 Lenalidomide (Revlimid)
5.2.2.3 Arsenic trioxide (Trisenox)
5.2.2.4 Plerixafor (Mozobil)
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)
7.4.1 Failure Rate
7.4.2 Clinical Trial Duration
7.4.3 Clinical Trial Size
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AB Science SA
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 AbbVie Inc.
9.3 Ablynx NV
9.4 Acceleron Pharma Inc.
9.5 IGF Oncology LLC.
9.6 ImmunGene Inc.
9.7 Millennium Pharmaceuticals Inc.
9.8 MimiVax LLC
9.9 Mirna Therapeutics
9.10 RedHill Biopharma Ltd.
9.11 Rhizen Pharmaceuticals S.A.
9.12 Terpenoid Therapeutics Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
